ALX Oncology received FDA clearance for its Investigational New Drug (IND) application for ALX2004, an antibody-drug conjugate (ADC) designed to treat EGFR-expressing solid tumors. The company plans to initiate a Phase 1 clinical trial in mid-2025, with initial safety data expected in the first half of 2026. ALX2004 is the first ADC developed from ALX Oncology’s proprietary linker-payload platform and was designed entirely in-house.
This IND clearance is a crucial step for ALX Oncology as it represents the company’s first foray into the ADC space and marks the transition of its proprietary linker-payload platform from research to clinical development. The advancement of ALX2004 diversifies the company’s pipeline beyond its lead candidate, evorpacept, and establishes its presence in the targeted cancer therapy arena. Specifically, the targeting of EGFR with an ADC offers a novel approach to treating various solid tumors with high unmet medical need, given the limitations of existing EGFR-targeted therapies. Successfully bringing an EGFR-targeted ADC to market could significantly impact treatment paradigms for several cancers, including breast cancer, colorectal carcinoma, head and neck squamous cell carcinoma, and non-small cell lung cancersmall cell lung cancer.
ALX2004 is designed with an optimized antibody backbone for enhanced anti-EGFR activity, a highly stable linker, and a proprietary topoisomerase I inhibitor payload intended to maximize the bystander effect. This unique combination of elements aims to overcome limitations observed in earlier-generation EGFR-targeted ADCs, which faced challenges related to drug design, on-target off-tumor toxicities, and the efficacy of their payloads. The Phase 1 trial will assess the safety and efficacy of ALX2004 as a single agent in patients with EGFR-expressing tumors. The company plans to host an R&D call in Q2 2025 to discuss ALX2004 in more detail.
The FDA clearance for ALX2004 sets the stage for clinical validation of ALX Oncology’s ADC platform. Positive clinical data could validate the company’s approach to ADC development, potentially attracting partnerships or further investment. The progress of ALX2004 will be a key indicator of the company’s future direction and its ability to translate innovative research into effective cancer therapies. The results of the upcoming Phase 1 trial will be critical in determining the future development trajectory of this potentially first-in-class therapy.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
